Sanofi’s Sarclisa Steals A March On Darzalex In Myeloma With FDA First-Line Nod

The Paris-headquartered major's anti-CD38 antibody has long lived in the shadow of Johnson & Johnson and Genmab’s Darzalex but the drug has secured approval in a first-line multiple myeloma setting ahead of its rival which should boost its sales significantly.